To explore the contribution of T cells to the anti-tumor effect of zebularine, we used monoclonal antibodies (mAb) to target CD4+ or CD8+ T cells in zebularine-treated tumor-bearing immunocompetent C57BL/6 mice. Here, CD8A is linked to neoplasm.